Loading...
Sofosbuvir-based regimens are currently approved for the treatment of hepatitis C virus (HCV) infection. However, the most effective sofosbuvir-based regimens for genotype 1 infection still include interferon, and few data are available regarding the efficacy in treatment-experienced patients.
To test the safety and efficacy of two interferon-free, sofosbuvir-based regimens in patients with HCV genotype 1 infection, researchers enrolled 113 patients (including 38 prior null responders and 19 with cirrhosis) to receive sofosbuvir (400 mg daily) and ledipasvir (90 mg daily) plus ribavirin (1000–1200 mg daily) for 6 weeks or 12 weeks, or sofosbuvir and GS-9669 (500 mg daily) plus ribavirin for 12 weeks. The primary endpoint was sustained virolo…